depot medroxyprogesterone subcutaneous Depo-SubQ Provera
Selected indexed studies
- Ovulation suppression following subcutaneous administration of depot medroxyprogesterone acetate. (Contracept X, 2022) [PMID:35281554]
- Clinical trial to evaluate pharmacokinetics and pharmacodynamics of medroxyprogesterone acetate after subcutaneous administration of Depo-Provera. (Fertil Steril, 2021) [PMID:33485608]
- Pharmacokinetics of subcutaneous depot medroxyprogesterone acetate injected in the upper arm. (Contraception, 2014) [PMID:23993431]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Progestin-only contraception: injectables and implants. (2014) pubmed
- Society of Family Planning committee consensus on self-administration of subcutaneous depot medroxyprogesterone acetate (DMPA-SC). (2022) pubmed
- Ovulation suppression following subcutaneous administration of depot medroxyprogesterone acetate. (2022) pubmed
- Clinical trial to evaluate pharmacokinetics and pharmacodynamics of medroxyprogesterone acetate after subcutaneous administration of Depo-Provera. (2021) pubmed
- Pharmacokinetics of subcutaneous depot medroxyprogesterone acetate injected in the upper arm. (2014) pubmed
- Return to fertility after subcutaneous depot medroxyprogesterone acetate: a narrative review. (2025) pubmed
- Implementation strategies to scale up self-administered depot medroxyprogesterone acetate subcutaneous injectable contraception: a scoping review. (2023) pubmed
- Suppression of ovulation and pharmacokinetics following subcutaneous administration of various doses of Depo-Provera®: a randomized trial. (2021) pubmed
- A randomized crossover study to evaluate local tolerability following subcutaneous administration of a new depot medroxyprogesterone acetate contraceptive formulation. (2023) pubmed
- Interest in self-administration of subcutaneous depot medroxyprogesterone acetate in the United States. (2016) pubmed